A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports

Brain metastasis (BM) from breast cancer has poor prognosis despite new advances and multi-modality treatments. No current data is guiding the use of palbociclib in the management of hormone receptor (HR)-positive breast cancer patients with BM as these patients were excluded systematically from all...

Descripción completa

Detalles Bibliográficos
Autores principales: Abusanad, Atlal, Al Hashem, Hashem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983625/
https://www.ncbi.nlm.nih.gov/pubmed/33790765
http://dx.doi.org/10.1159/000514190
_version_ 1783667936879181824
author Abusanad, Atlal
Al Hashem, Hashem
author_facet Abusanad, Atlal
Al Hashem, Hashem
author_sort Abusanad, Atlal
collection PubMed
description Brain metastasis (BM) from breast cancer has poor prognosis despite new advances and multi-modality treatments. No current data is guiding the use of palbociclib in the management of hormone receptor (HR)-positive breast cancer patients with BM as these patients were excluded systematically from all phase 3 trials. Here, we report an evident clinical response from combining palbociclib with endocrine therapy in HR-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with BM.
format Online
Article
Text
id pubmed-7983625
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-79836252021-03-30 A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports Abusanad, Atlal Al Hashem, Hashem Case Rep Oncol Case Report Brain metastasis (BM) from breast cancer has poor prognosis despite new advances and multi-modality treatments. No current data is guiding the use of palbociclib in the management of hormone receptor (HR)-positive breast cancer patients with BM as these patients were excluded systematically from all phase 3 trials. Here, we report an evident clinical response from combining palbociclib with endocrine therapy in HR-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with BM. S. Karger AG 2021-03-12 /pmc/articles/PMC7983625/ /pubmed/33790765 http://dx.doi.org/10.1159/000514190 Text en Copyright © 2021 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Abusanad, Atlal
Al Hashem, Hashem
A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports
title A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports
title_full A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports
title_fullStr A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports
title_full_unstemmed A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports
title_short A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports
title_sort substantial response from adding palbociclib to endocrine therapy in brain metastasis from hormone receptor-positive, her2-negative breast cancer: case reports
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983625/
https://www.ncbi.nlm.nih.gov/pubmed/33790765
http://dx.doi.org/10.1159/000514190
work_keys_str_mv AT abusanadatlal asubstantialresponsefromaddingpalbociclibtoendocrinetherapyinbrainmetastasisfromhormonereceptorpositiveher2negativebreastcancercasereports
AT alhashemhashem asubstantialresponsefromaddingpalbociclibtoendocrinetherapyinbrainmetastasisfromhormonereceptorpositiveher2negativebreastcancercasereports
AT abusanadatlal substantialresponsefromaddingpalbociclibtoendocrinetherapyinbrainmetastasisfromhormonereceptorpositiveher2negativebreastcancercasereports
AT alhashemhashem substantialresponsefromaddingpalbociclibtoendocrinetherapyinbrainmetastasisfromhormonereceptorpositiveher2negativebreastcancercasereports

Ejemplares similares